Frequency of Epstein‐Barr virus‐specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients
- 24 May 2002
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 67 (3), 359-363
- https://doi.org/10.1002/jmv.10073
Abstract
Undifferentiated nasopharyngeal carcinoma is very common among Southern Chinese. While most patients have the disease detected and treated early, those who are diagnosed with advanced stages face a poor prognosis. Nasopharyngeal carcinoma is associated with latent Epstein-Barr virus (EBV); it was suggested previously that a cytotoxic T-lymphocyte (CTL)-based therapy targeting EBV proteins may offer a possible new form of treatment for this disease. The most likely target of this treatment is latent membrane protein 2 (LMP2). To define further the preexisting level of anti-EBV immunity in Chinese subjects, the frequency of peripheral blood mononuclear cells (PBMCs) responding to peptide epitopes was determined using an ELISPOT assay in 50 healthy control blood donors and in 26 patients newly diagnosed with nasopharyngeal carcinoma. A total of 7 LMP2, 2 LMP1, 1 EBNA3A, and 1 EBNA3B epitopes were used in a HLA-restricted manner. As reported previously for healthy virus carriers in western countries, it was found that in both groups the strongest responses were to epitopes in the EBNA proteins with weaker responses to the LMP epitopes. It was found that LMP2 epitopes were recognized in a greater percentage of both groups than previously reported, due most likely to the greater sensitivity of the ELISPOT method. However, patients with nasopharyngeal carcinoma demonstrated a weaker response than that displayed by healthy control subjects to several epitopes. The results demonstrate that LMP2 epitopes are recognized widely in an HLA-restricted manner in patients with nasopharyngeal carcinoma and that immunotherapy to boost preexisting immunity to these epitopes may offer a viable method to treat such patients or to protect against recurrence. J. Med Virol. 67:359–363, 2002.Keywords
This publication has 17 references indexed in Scilit:
- CTL Control of EBV in Nasopharyngeal Carcinoma (NPC): EBV-Specific CTL Responses in the Blood and Tumors of NPC Patients and the Antigen-Processing Function of the Tumor CellsPublished by The American Association of Immunologists ,2000
- Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytesEuropean Journal of Immunology, 1998
- Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allograftsImmunological Reviews, 1997
- Adoptive cellular immunotherapy for EBV lymphoproliferative diseasesImmunological Reviews, 1997
- Phototyping: comprehensive DNA typing for HLA‐A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence‐specific primers (PCR‐SSP)Tissue Antigens, 1995
- Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1Nature, 1995
- RAPID CHARACTERIZATION OF HLA CLASS I ALLELES BY GENE MAPPING USING ARMS PCREuropean Journal of Immunogenetics, 1995
- Retrospective analysis of nasopharyngeal carcinoma treated during 1976–1985: late complications following megavoltage irradiationThe British Journal of Radiology, 1992
- Epstein–Barr virus and carcinomas: Undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virusThe Journal of Pathology, 1991
- Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patientsInternational Journal of Cancer, 1983